

Primary Care Network (PCN) Governance for the Safe and Secure Handling of the COVID-19 Vaccines

Policy Ref No: 002

Version/Status: 1.0 / FINAL

Responsible Committee: Governing Body

Date Approved: 11 December 2020

Author: Helen Foster / Medicines Optimisation Lead

Responsible Lead: Neil Smurthwaite, Chief Operating Officer

Review Date: December 2021

Version History

Version No.	Date	Author	Document Status	Commentary:	Circulation
0.1	11/12/20	Helen Foster / Medicines Optimisation Lead	Draft	To be approved under Governing Body Urgent Decision Making arrangements as set out in the CCG Constitution (9.13.3)	<ul style="list-style-type: none"> - Dr Steven Cleasby, CCG Chair; - Robin Tuddenham, Accountable Officer; - Neil Smurthwaite, Chief Operating Officer; - Penny Woodhead, Chief Quality and Nursing Officer; - Dr James Gray, GP Member; - Dr Rob Atkinson; Secondary Care Specialist
1.0	11/12/20	Andrew O'Connor Senior Corporate Governance Officer	Final	Approved under Governing Body Urgent Decision Making arrangements as set out in the CCG Constitution (9.13.3)	<ul style="list-style-type: none"> - Governing Body - Helen Foster (Medicines Optimisation Lead) - CCG Website

Contents

1. Introduction and Purpose	4
2. Aims and Objectives	4
3. Scope of the Policy	5
4. Roles and Responsibilities.....	5
5. Policy Details	5
6. Appendices.....	11
Appendix 1 Links to relevant National Standards.....	11

1. Introduction and Purpose

The COVID-19 vaccination programme is of the highest priority for the NHS. In order to deliver this programme both safely and effectively, good practice in the handling and management of vaccine is paramount. It is anticipated that a number of COVID-19 vaccines will be introduced during 2020 and 2021, so good governance is essential. Clarity of both the overarching principles and the detailed 'standard operating procedures' are required to enable safe, effective implementation and delivery of the vaccination programme. This document is to be read alongside the Standard Operating Procedure documentation developed for all COVID-19 vaccines and all environments in which they are handled.

This policy document enables corporate and professional governance for use of the COVID-19 vaccines, with the expectation that all areas detailed are addressed locally and that standard NHS medicines governance arrangements are in place.

The document is intended to provide the overarching principles for robust governance of the safe and secure handling and management of COVID-19 vaccines in the end-to-end supply chain for the vaccination programme.

2. Aims and Objectives

- To ensure that all staff involved in delivery of the vaccination programme are aware of, and adhere to, the correct procedures for the ordering, receipt, storage, supply and administration of the product.
- To ensure that the physical and biochemical integrity and sterility of all vaccines and related medicines is maintained.
- To ensure that all staff involved in delivery of the vaccination programme are aware of the relevant characteristics of COVID-19 vaccines and the implications this has for vaccine efficacy and patient safety.
- To provide assurance that vaccine safety, sterility, quality and efficacy is protected.
- To define key roles and responsibilities needed to deliver this assurance.

- To ensure that all staff understand their critical roles and responsibilities in delivering these objectives.

3. Scope of the Policy

All staff responsible for planning and managing the primary care COVID-19 vaccination programme in 2020/21 and Pharmacy staff engaged in supporting and delivering the COVID-19 vaccination programme in 2020/21.

4. Roles and Responsibilities

The legal entity responsible for operating the vaccination site is to assign responsibility for clinical and operational oversight.

The PCN Clinical Director is responsible for service provision, aided by the relevant Primary Care Lead Pharmacist to ensure safe and secure handling and management of the COVID-19 vaccine and related medicines.

The CCG Governing Body is responsible for the approval and review of this policy.

5. Policy Details

COVID-19 Vaccines

There are a number of COVID-19 vaccines under development and it is anticipated that a range will be utilised in the vaccination programme. None will be authorised at the start of the programme so initially they will be unlicensed products temporarily authorised for supply under Regulation 174 of the Human Medicines Regulations 2012. This regulation enables the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise use of a product on a temporary basis in response to the spread of pathogenic agents.

The characteristics of the different vaccines may vary considerably and will increase in clarity over time. Prior to licensing the product characteristics are

available in the relevant 'Healthcare Professional Factsheet' and patient information in the 'Consumer Factsheet'. Following award of the Marketing Authorisation this information is available in the Summary of Product Characteristics and Patient Information leaflet respectively. The first requires transport and storage under ULT conditions (-70 +/- 10 C). This may not be the case for those that follow, but cold chain will be critical for all. Use of vaccines that have deviated from recommended storage or transportation conditions risks compromising vaccine efficacy and patient safety. Vaccines that have not been transported or stored correctly may be ineffective or harmful; they would therefore no longer be within the terms of their product authorisation or temporary regulation 174 authorisation and must not be used. Means of detecting when a temperature excursion has occurred are required. The focus on avoidance of waste should also be of high priority.

Further information concerning COVID-19 vaccines is available in the Public Health England publication ['COVID-19 vaccination programme Information for healthcare practitioners'](#)

Legal framework and practice standards

All activity is to be undertaken in accordance with the Human Medicines Regulations 2012, as amended by the Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020.

Adherence to national standards of good practice is required including those set by the Care Quality Commission, the National Institute for Health and Care Excellence, Public Health England and the Royal Pharmaceutical Society of Great Britain, as detailed in the Appendix 1 below.

Accountability and responsibility for vaccines, associated medicines and their supply chain

- The PCN Clinical Director is accountable for the safe and secure handling and management of medicines on all vaccination sites operating within or

under the jurisdiction of their employing legal entity. This includes oversight of those elements of practice within designated vaccination sites that may impact upon product integrity, from receipt of product to vaccine administration. The PCN Clinical Director will be aided by the relevant Primary Care Lead Pharmacist.

- Calderdale CCG Governing Body will ensure that the above named individuals are documented.
- The PCN Clinical Director may delegate operational responsibility for oversight of ordering, receipt, storage and safe handling of vaccines and medicines, to a named and suitably trained member of staff on each vaccination site, aided by the relevant Primary Care Lead Pharmacist.
- This responsibility extends to oversight of issue of vaccines and medicines to roving vaccinators and for administration of vaccines by PCN staff within care homes.
- The Specialist Pharmacy Services Regional Quality Assurance Specialists will work with the Primary Care Lead Pharmacist to provide specialist pharmaceutical expertise in the development of systems and processes of work to ensure the safe and secure handling of the vaccine.

Handling and management of vaccine and medicines in vaccination sites

The PCN Clinical Director must ensure that all activities are carried out in accordance with:

- This policy document
- The relevant nationally authored documents and Standard Operating Procedures (SOPs)
- Relevant local organisational medicines policies
- Standard good practice guidance including aseptic technique
- Relevant Health and Safety guidance

- National Standards including those detailed in Appendix 1

Local amendments to this policy

Any amendments to this policy or relevant SOPs must be ratified by the CCG's Governing Body.

Staff authorisation to be supplied with and administer COVID-19 Vaccines

The Primary Care Lead Pharmacist must ensure that appropriate and formal authorisation for vaccine administration is in place such as a Patient Group Direction, protocol or written instruction, and that the staff groups who are supplied with, prepare, and administer the COVID-19 vaccine are those defined as eligible to do so.

Safety and security of vaccines and related medicines

The Primary Care Lead Pharmacist must ensure that that safe and secure handling and storage of vaccine and medicines are in place in accordance with principles and guidance encompassed in ['Professional guidance on the safe and secure handling of medicines'](#) (Royal Pharmaceutical Society of Great Britain).

Storage and transportation of vaccines

The 'cold chain' is a term used to describe the cold temperature conditions in which certain products need to be kept during storage and distribution. Maintaining the cold chain ensures that vaccines are transported and stored according to the manufacturer's recommended temperature range until the point of administration.

Vaccines must be stored at the correct temperature and transported only in approved and validated packaging, and the temperature of the vaccine carrier and contents monitored and reviewed before use.

The Primary Care Lead Pharmacist must ensure that storage and transportation are undertaken in accordance with the relevant SOPs, that cold chain temperatures are monitored correctly and that any 'out of specification' recordings are addressed promptly and appropriately, and that a full audit trail is maintained. Further details are included in the relevant SOPs and in manufacturers' information.

Workforce and training

All staff undertaking duties at the vaccination site must meet the necessary training standards and competencies in line with the SOPs and standard organisational processes. A training needs assessment is required for the roles within the vaccination services, with corresponding training materials and assessment process, to enable timely and focussed workforce development.

As detailed in 'Professional guidance on the safe and secure handling of medicines (Royal Pharmaceutical Society of Great Britain)' (see Appendix 1) 'the named individual ensures that accountable individuals are competent and supported in their role as it relates to the safe and secure handling of medicines'.

The roles assigned to support the rollout of COVID-19 vaccination need to be in accordance with legislation including that detailed in the Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020.

Precautions

Anaphylaxis kits including injections of intramuscular adrenaline 1:1,000 must be in date and readily available at all locations undertaking vaccination.

Any needlestick or other injuries must be addressed in accordance with the policies of the relevant employing legal entity.

Maintenance of records

All records must be maintained in accordance with relevant SOPs. These include the ordering, receipt and issue of vaccines, tracking of product, plus patient focused records including consent and administration.

Any serious adverse reactions are to be escalated for immediate senior clinical input; such situations are to be fully documented following the event and a record kept of relevant product batch numbers. A record of all serious adverse events is to be provided to the Primary Care Lead Pharmacist.

Data Protection

All staff have a responsibility to ensure that they do not disclose information about the service, service users, staff members and corporate documentation to unauthorised individuals.

Disposal of vaccines and other waste

Disposal of waste vaccines and any sharps must be undertaken in a safe and secure manner in accordance with relevant SOPs.

If any packaging includes dry ice this must also be disposed of in a safe and secure manner using appropriate personal protective equipment.

Business Continuity Planning

The Primary Care Lead Pharmacist will be responsible for establishing an agreed business continuity plan in relation to safe and secure handling of vaccines, and for testing this plan in line with the organisational emergency preparedness processes and [NHS Core Standards for Emergency Preparedness, Resilience and Response](#). The business continuity plan should detail how the relevant aspects of the service will respond, recover and manage during disruption relating to people, information, security, premises

including utilities, facilities particularly refrigerator (and if relevant ULT) failure, supplier, IT and data.

6. Appendices

Appendix 1 Links to relevant National Standards

[CQC Regulation 12: Safe Care and Treatment](#)

The intention of this regulation is to prevent people from receiving unsafe care and treatment and prevent avoidable harm or risk of harm. Providers must assess the risks to people's health and safety during any care or treatment and make sure that staffs have the qualifications, competence, skills and experience to keep people safe.

- Providers must make sure that the premises and any equipment used is safe and where applicable, available in sufficient quantities. Medicines must be supplied in sufficient quantities, managed safely and administered appropriately to make sure people are safe.
- Providers must prevent and control the spread of infection. Where the responsibility for care and treatment is shared, care planning must be timely to maintain people's health, safety and welfare.

The CQC understands that there may be inherent risks in carrying out care and treatment, and we will not consider it to be unsafe if providers can demonstrate that they have taken all reasonable steps to ensure the health and safety of people using their services and to manage risks that may arise during care and treatment'

[NICE Clinical Guideline QS61: Infection Prevention and Control](#)

This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings.

[The Green Book - Immunisation against infectious disease \(Public Health England\)](#)

The latest information on vaccines and vaccination procedures, for vaccine preventable infectious diseases in the UK. The COVID-19 vaccine chapter is available on the gov.uk website in the immunisation section under guidance and regulation: [COVID-19: the green book, chapter 14a](#)

Professional guidance on the safe and secure handling of medicines (Royal Pharmaceutical Society of Great Britain)

Adhere to the [documented governance principles and relevant guidance](#).